Literature DB >> 26055667

Inherited metabolic disorders in Turkish patients with autism spectrum disorders.

Ertugrul Kiykim1, Cigdem Aktuglu Zeybek1, Tanyel Zubarioglu1, Serif Cansever1, Cengiz Yalcinkaya2, Erdogan Soyucen1, Ahmet Aydin1.   

Abstract

Autism spectrum disorders (ASDs) are a major health problem because of their high prevalence in the general population. The pathophysiology of ASD remains unclear, although genetic defects may be detected in 10-20% of affected patients. Among these cases, the prevalence of inherited metabolic disorders (IMD) has not been extensively evaluated. IMDs responsible for ASDs are usually identified via clinical manifestations such as microcephaly, dysmorphic features, convulsions, and hepatosplenomegaly. Infrequently, patients with no additional clinical symptoms suggestive of an IMD may be diagnosed as having an idiopathic ASD. High consanguinity rates have resulted in an increased prevalence of IMDs in the Turkish population. The aim of this study was to explore the benefits of systematic screening for IMD among Turkish patients with ASDs. In our study, data were retrospectively collected for 778 children with ASDs. In all cases, the metabolic investigations included an arterial blood gas analysis, serum ammonia and lactate levels, a quantitative plasma amino acid analysis, a whole blood acylcarnitine profile via tandem mass spectrometry and a urine organic acid profile. Urinary glycosaminoglycan levels and homocysteine levels were screened in selected cases; 300 of the 778 patients with ASDs whose physical and metabolic investigations were complete and met this study's criteria were enrolled. Among the 300 children with autism, IMD were diagnosed in nine patients as follows: two patients were diagnosed with phenylketonuria, and one patient was diagnosed with partial biotinidase deficiency; one patient was diagnosed with mucopolysaccharidosis type III, and one patient was diagnosed with classical homocystinuria; one patient was diagnosed with glutaric acidemia type 1, and one patient was diagnosed with short chain acyl-CoA dehydrogenase deficiency; one patient was diagnosed with argininemia, and one patient was diagnosed with L-2-hydroxyglutaric aciduria.
© 2015 International Society for Autism Research, Wiley Periodicals, Inc.

Entities:  

Keywords:  autism spectrum disorders; incidence; inherited metabolic disorders; metabolic screening

Mesh:

Substances:

Year:  2015        PMID: 26055667     DOI: 10.1002/aur.1507

Source DB:  PubMed          Journal:  Autism Res        ISSN: 1939-3806            Impact factor:   5.216


  7 in total

1.  Identification of the Genetic Cause for Childhood Disintegrative Disorder by Whole-Exome Sequencing.

Authors:  Zhu Wen; Tian-Lin Cheng; Da-Zhi Yin; Shi-Bang Sun; Zheng Wang; Shun-Ying Yu; Yi Zhang; Zilong Qiu; Ya-Song Du
Journal:  Neurosci Bull       Date:  2017-03-10       Impact factor: 5.203

2.  A Subset of Patients With Autism Spectrum Disorders Show a Distinctive Metabolic Profile by Dried Blood Spot Analyses.

Authors:  Rita Barone; Salvatore Alaimo; Marianna Messina; Alfredo Pulvirenti; Jean Bastin; Alfredo Ferro; Richard E Frye; Renata Rizzo
Journal:  Front Psychiatry       Date:  2018-12-07       Impact factor: 4.157

3.  Evaluation of clinical, neuroradiologic, and genotypic features of patients with L-2-hydroxyglutaric aciduria.

Authors:  Tanyel Zübarioğlu; Cengiz Yalçınkaya; Çiğdem Oruç; Ertuğrul Kıykım; Mehmet Şerif Cansever; Alper Gezdirici; Gözde Yeşil; Ece Öge Enver; Çiğdem Aktuğlu Zeybek
Journal:  Turk Pediatri Ars       Date:  2020-09-23

4.  Application of metabolomics: Focus on the quantification of organic acids in healthy adults.

Authors:  Dimitris Tsoukalas; Athanasios Alegakis; Persefoni Fragkiadaki; Evangelos Papakonstantinou; Dragana Nikitovic; Aikaterini Karataraki; Alexander E Nosyrev; Emmanouel G Papadakis; Demetrios A Spandidos; Nikolaos Drakoulis; Aristides M Tsatsakis
Journal:  Int J Mol Med       Date:  2017-05-10       Impact factor: 4.101

Review 5.  Effects of l-Carnitine in Patients with Autism Spectrum Disorders: Review of Clinical Studies.

Authors:  Michele Malaguarnera; Omar Cauli
Journal:  Molecules       Date:  2019-11-22       Impact factor: 4.411

Review 6.  Involvements of Hyperhomocysteinemia in Neurological Disorders.

Authors:  Marika Cordaro; Rosalba Siracusa; Roberta Fusco; Salvatore Cuzzocrea; Rosanna Di Paola; Daniela Impellizzeri
Journal:  Metabolites       Date:  2021-01-06

7.  Gene-Environment Interactions in Developmental Neurotoxicity: a Case Study of Synergy between Chlorpyrifos and CHD8 Knockout in Human BrainSpheres.

Authors:  Sergio Modafferi; Xiali Zhong; Andre Kleensang; Yohei Murata; Francesca Fagiani; David Pamies; Helena T Hogberg; Vittorio Calabrese; Herbert Lachman; Thomas Hartung; Lena Smirnova
Journal:  Environ Health Perspect       Date:  2021-07-14       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.